ResMed investors sleep soundly | Figma pops 250% on IPO | Ozempic faces a new challenger
ResMed beats full‑year earnings and revenue forecasts thanks to a growth in snorers around the world.
Figma, the design software, has tripled its market value on its IPO debut in one of the biggest first day pops for a US software company ever.
Novo Nordisk, the company behind Ozempic, has seen market value slashed by over €60 billion after investors worry it’s losing the obesity drug race.
_
Download the free app (App Store): http://bit.ly/FluxAppStore
Download the free app (Google Play): http://bit.ly/FluxappGooglePlay
Daily newsletter: https://bit.ly/fluxnewsletter
Flux on…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.